elapsed_time: 18s
was_input_captured: True
original_text: |
    Has had disease progression on more than two cyclin-dependent kinase (CDK)4/6 inhibitors. Adjuvant abemaciclib is allowed but must have progressed on palbociclib or ribociclib.
inclusion: False
